Hikma Pharmaceuticals Plc Annual Information Update (1264F)
April 17 2014 - 11:42AM
UK Regulatory
TIDMHIK
RNS Number : 1264F
Hikma Pharmaceuticals Plc
17 April 2014
Annual Information Update
London, 17 April 2014. In accordance with Prospectus Rule 5.2,
Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK)
sets out below a summary of the information which has been
published or made available to the public over the period. The
information referred to in this Update was up to date at the time
the information was published, but some information may now be out
of date.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory
Information Service, may be viewed and downloaded from the
Company's market news section on the London Stock Exchange website
at
(http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm)
or from the press releases page on the Company's website at
(http://www.hikma.com/investorrelations/rns/). The Stock Exchange
announcements made during the period were:
Date Headline
----------- -----------------------------------------------
14/04/2014 Director/PDMR Shareholding
----------- -----------------------------------------------
07/04/2014 Blocklisting Interim Review
----------- -----------------------------------------------
07/04/2014 Total Voting Rights
----------- -----------------------------------------------
02/04/2014 Successful resolution to US FDA warning letter
----------- -----------------------------------------------
24/03/2014 Director/PDMR Shareholding
----------- -----------------------------------------------
12/03/2014 Directorate Change
----------- -----------------------------------------------
12/03/2014 Final Results
----------- -----------------------------------------------
27/02/2014 Notification of major interests in shares
----------- -----------------------------------------------
21/02/2014 Block Listing of Shares
----------- -----------------------------------------------
14/02/2014 Trading Statement
----------- -----------------------------------------------
11/02/2014 Directorate Change
----------- -----------------------------------------------
30/12/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
20/12/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
20/12/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
16/12/2013 Total Voting Rights
----------- -----------------------------------------------
13/12/2013 Holding(s) in Company
----------- -----------------------------------------------
20/11/2013 Re Agreement
----------- -----------------------------------------------
11/11/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
08/11/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
08/11/2013 Interim Management Statement
----------- -----------------------------------------------
25/10/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
23/10/2013 Holding(s) in Company
----------- -----------------------------------------------
18/10/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
04/10/2013 Dividend Declaration
----------- -----------------------------------------------
01/10/2013 Blocklisting Interim Review
----------- -----------------------------------------------
01/10/2013 Total Voting Rights
----------- -----------------------------------------------
18/09/2013 Hikma entering Ethiopian pharmaceutical market
----------- -----------------------------------------------
02/09/2013 Transaction in Own Shares
----------- -----------------------------------------------
29/08/2013 Transaction in Own Shares
----------- -----------------------------------------------
21/08/2013 Interim Results
----------- -----------------------------------------------
31/07/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
19/07/2013 Total Voting Rights
----------- -----------------------------------------------
08/07/2013 Trading Statement
----------- -----------------------------------------------
05/07/2013 Holding(s) in Company
----------- -----------------------------------------------
01/07/2013 Signing of Exclusive Agreement with Theravance
----------- -----------------------------------------------
20/06/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
03/06/2013 Total Voting Rights
----------- -----------------------------------------------
28/05/2013 Holding(s) in Company
----------- -----------------------------------------------
23/05/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
21/05/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
20/05/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
16/05/2013 Result of AGM
----------- -----------------------------------------------
16/05/2013 Interim Management Statement
----------- -----------------------------------------------
10/05/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
02/05/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
23/04/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
18/04/2013 Director/PDMR Shareholding
----------- -----------------------------------------------
17/04/2013 Hikma update on global Injectables business
----------- -----------------------------------------------
10/04/2013 Annual Financial Report
----------- -----------------------------------------------
All of the above announcements were also made by the Company via
the Nasdaq Dubai stock exchange CANDI system. These announcements
may be viewed and downloaded from the Nasdaq Dubai website
(www.candi.nasdaq.com).
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial
Services Authority ("FSA") visa the National Storage Mechanism over
the previous 12 months. These documents are available at
http://www.hemscott.com/nsm.do or at the Company's registered
office.
Date Document
-------------- ----------------------------------------
10 April 2014 Annual Report and Accounts 2013
-------------- ----------------------------------------
10 April 2014 Notice of 2014 Annual General Meeting
-------------- ----------------------------------------
10 April 2014 Proxy forms for the 2014 Annual General
Meeting
-------------- ----------------------------------------
10 April 2013 Annual Report and Accounts 2012
-------------- ----------------------------------------
10 April 2013 Notice of 2013 Annual General Meeting
-------------- ----------------------------------------
10 April 2013 Proxy forms for the 2013 Annual General
Meeting
-------------- ----------------------------------------
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in
England and Wales as detailed in the table below.
Date Filed Form Description
-------------- ------ ---------------------------------------
05/04/2013 SH01 Statement of Capital GBP 19,748,436.90
-------------- ------ ---------------------------------------
Authorised Allotment of Shares and
24/05/2013 RES10 Debentures
-------------- ------ ---------------------------------------
Group of Companies' Accounts made up
02/07/2013 AA to 31/12/12
-------------- ------ ---------------------------------------
19/07/2013 SH01 Statement of Capital GBP 19,794,212.80
-------------- ------ ---------------------------------------
11/09/2013 AR01 Annual Return - No Member List
-------------- ------ ---------------------------------------
Registration of a Charge / Charge Code
25/09/2013 MR01 055579340002
-------------- ------ ---------------------------------------
Return of Purchase of Own Shares -
07/10/2013 SH03 Treasury Capital GBP 21,000
-------------- ------ ---------------------------------------
10/10/2013 SH01 Statement of Capital GBP 19,796,502.80
-------------- ------ ---------------------------------------
07/04/2014 SH01 Statement of Capital GBP 19,815,699.70
-------------- ------ ---------------------------------------
07/04/2014 SH01 Statement of Capital GBP 19,815,699.70
-------------- ------ ---------------------------------------
Copies of all these documents may be obtained from Companies
House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a
registered user, they may be viewed and downloaded using Companies
House "Webcheck" at www.companieshouse.gov.uk.
Further Information
Copies of all documents can be obtained from the Company at the
registered office which is located at 13 Hanover Square, London W1S
1HW.
Peter Speirs
Company Secretary
17 April 2014
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2013, Hikma achieved
revenues of $1,365 million and profit attributable to shareholders
of $212 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AIUEDLFFZZFZBBF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
